Perception of risk: The state of COX-2 selective inhibitors Lee S. SimonVibeke Strand Invited Commentary Pages: 163 - 166
Treatment of reactive arthritis with azithromycin Christopher T. Ritchlin Clinical Trials Report Pages: 171 - 171
Doxycycline in undifferentiated spondyloarthropathy Christopher T. Ritchlin Clinical Trials Report Pages: 171 - 172
Gut inflammation in the spondyloarthropathies Herman MielantsFilip De KeyserFilip Van den Bosch OriginalPaper Pages: 188 - 194
What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death? Christopher W. WuRobert Terkeltaub Clinical Trials Report Pages: 211 - 212
Calcium-containing crystals and osteoarthritis: Implications for the clinician Christopher W. WuRobert TerkeltaubKenneth C. Kalunian OriginalPaper Pages: 213 - 219
Diet, alcohol, and gout: How do we advise patients given recent developments? Hyon K. Choi OriginalPaper Pages: 220 - 226
Renal urate handling: Clinical relevance of recent advances Naohiko AnzaiAtsushi EnomotoHitoshi Endou OriginalPaper Pages: 227 - 234
Recent advances in the epidemiology of gout Kenneth G. SaagTed R. Mikuls OriginalPaper Pages: 235 - 241
Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care? Ted R. MikulsKenneth G. Saag OriginalPaper Pages: 242 - 249